Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jun 5;24(19):4734–4744. doi: 10.1158/1078-0432.CCR-17-1523

Figure 1. Subject selection from bevacizumab-induced hypertension extreme phenotypes in CALGB 80405.

Figure 1

Abbreviations used: HTN, hypertension; PG, pharmacogenetic; BV, bevacizumab; AE, adverse event; tx, treatment; QC, quality control.